Urological Endoscope Market Size, Share & Trend Analysis - Global - 2025-2031 - Includes: Cytoscope Market, Ureteroscope Market, and 2 more
Description
Global Urological Endoscope Market Report, 2025 Edition
Executive Summary
The global urological endoscope market was valued at over $1.4 billion in 2024. The market is projected to grow at a 12.9 percent CAGR, reaching $3.4 billion by 2032. This rapid expansion is driven by rising BPH and urinary stone prevalence, the shift toward minimally invasive treatment protocols, heightened infection control awareness, and the accelerating adoption of single-use endoscopes.
This report covers all major categories of urological endoscopes, including single-use, rigid, and reusable flexible cystoscopes; single-use, semi-rigid, and reusable flexible ureteroscopes; rigid resectoscopes; and rigid nephroscopes. Reusable flexible scopes are further divided into fiber optic and video types. Only new endoscope sales are included in this analysis. Refurbished scopes and repair services are excluded.
The study provides units sold, average selling prices, market values, competitive shares, procedure trends, and growth patterns. It includes drivers and limiters, regional demand variation, competitive dynamics, business strategies, and technological innovations. Forecasts extend to 2032, with historical data to 2022.
COVID-19 significantly accelerated single-use adoption. While reusable endoscopes remain dominant, single-use formats have gained strong momentum, especially in infection-sensitive hospitals and high-volume settings where repair costs and sterilization workflows are limiting factors. Meanwhile, rising global procedural volumes for BPH and stone disease continue to fuel overall endoscope demand.
This report provides a comprehensive overview of the global urological endoscope landscape, guiding decision-makers in product strategy, investment planning, competitive positioning, and technology evaluation.
Market Overview
Urological endoscopes are essential diagnostic and interventional tools used to evaluate and treat conditions of the urinary tract, including urinary stones, BPH, strictures, tumors, infections, and congenital abnormalities. They support minimally invasive procedures across urology departments, ambulatory surgery centers, and select outpatient facilities.
The market includes:
Cystoscopes (single-use, rigid, flexible reusable)
Ureteroscopes (single-use, semi-rigid, flexible reusable)
Resectoscopes (rigid)
Nephroscopes (rigid)
Flexible reusable scope categories include fiber optic and video-based models. Each device type serves specific diagnostic and procedural needs:
Cystoscopes are primarily used for bladder examination, tumor assessment, and urethral evaluation.
Ureteroscopes support stone management, strictures, and ureteral tumors.
Nephroscopes are used for percutaneous kidney access and stone removal procedures.
Resectoscopes facilitate BPH and some gynecologic resections.
Adoption varies by region, influenced by reimbursement policies, hospital purchasing capacity, infection control protocols, availability of trained urologists, and the rate of transition to single-use devices.
The market has been reshaped over the last several years by:
COVID-19 infection control practices
Increased attention to cross-contamination risks
Supply of single-use alternatives
Procedural growth tied to stone disease and BPH
Changes in urologist practice structures
Growing outpatient surgical volumes
Endoscope sales correlate closely with procedure volumes. As BPH and stone management grow due to demographic shifts and lifestyle trends, so does the demand for urological endoscopes.
Despite strong growth, hospitals must navigate capital budget limitations, reimbursement changes, and shifts toward refurbished alternatives in price-sensitive environments. These factors balance the short- and medium-term trajectory of each endoscope category.
Market Drivers
Shift to Single-Use Products
The COVID-19 pandemic was a major catalyst for single-use endoscope adoption. In bronchoscopy, single-use devices rapidly became essential tools, and this trend has since spilled into urology, where infection control concerns remain a high priority. Single-use scopes eliminate cross-contamination risk, reduce sterilization burden, and simplify workflow.
The urology market has historically relied on reusable scopes due to clinician familiarity, perceived cost savings, and high image quality. However, as single-use cystoscopes and ureteroscopes have improved, hospitals have expanded their use in outpatient clinics and emergency settings.
Although cost-effectiveness evidence remains mixed, the added infection control assurance and lower repair burden contribute to the growing momentum behind single-use use cases. As more models enter the market, procedure volumes linked to single-use endoscopes will increase.
Procedure Growth
Urological endoscope demand is tied closely to procedural volume. Cystoscopes, ureteroscopes, and nephroscopes are used in stone management, while resectoscopes are used in BPH treatment. These devices are also used in procedures beyond the scope of this report, such as gynecological resections and surveillance for bladder tumors.
As global populations age and healthcare access expands, hospitals treat a greater number of patients requiring:
Stone removal
Ureteral evaluations
Bladder tumor surveillance
BPH management
Urethral repairs
Higher procedure volume translates directly into stronger scope demand. Growth in minimally invasive surgeries also contributes to increased endoscope utilization and replacement cycles.
Demographic Factors
Demographics strongly influence urological procedure volumes. BPH and stone management procedures grow as the population ages. The male population over age 65 is projected to increase significantly during the forecast period. BPH symptoms appear rarely before age 40 but affect:
50 percent of men in their 50s
80 percent of men in their 70s
More than 95 percent of men over 80
Globally, about 22 million men have moderate to severe BPH symptoms. BPH prevalence ranges from 20 to over 60 percent of men over 50, depending on region.
Urinary stones are also tied closely to obesity. Approximately one-third of American adults are obese, and nearly 2 billion adults worldwide are overweight. Excess body weight increases urinary stone formation due to metabolic changes, higher excretion of stone-forming substances, and dietary patterns high in sodium, protein, and sugar.
As obesity rises globally, stone incidence increases, placing additional strain on healthcare systems but also expanding demand for scopes used in endoscopic stone management.
Market Limiters
Reimbursement Cuts
CMS readmission reduction and cost-containment policies in the United States have placed pressure on hospital budgets. Reduced capital income may limit spending on new urological endoscopes. Hospitals may rely more on existing inventory, delay capital purchases, or increase preference for refurbished scopes as cost-saving alternatives.
Similar trends appear in cost-sensitive countries where austerity measures and limited capital availability encourage hospitals to extend device life or pursue pre-owned equipment.
Urologist Practice Setting Changes
The number of small urology practices has been declining due to increasing malpractice costs and administrative overhead. As solo and small group practices close, urologists migrate to hospital employment or large specialty groups. This consolidation could limit device purchasing flexibility, since hospitals maintain centralized purchasing processes and may restrict the number of new devices procured annually.
As purchasing power consolidates, buying cycles can lengthen, affecting the pace at which facilities adopt new technologies.
Decline of Service Revenue
Historically, reusable scope manufacturers benefited from recurring repair and refurbishment revenue. As single-use devices expand and pricing decreases, reusable scope suppliers may be compelled to reduce service pricing to remain competitive. This erodes margins and pressures overall device pricing.
Simultaneously, single-use devices reduce repair needs, removing a historical revenue source for OEMs and service providers. Over time, as single-use scope adoption rises, reusable scope companies may face price compression across both capital and service categories.
Market Coverage and Data Scope
Quantitative Coverage
Market size
Market shares
Market forecasts to 2032
Growth rates
Units sold
Average selling prices
Qualitative Coverage
Market drivers and limiters
Technology shifts and adoption insights
Competitive strategies and SWOT profiles
Mergers and acquisitions
Product portfolios
Regulatory landscape
Disease and procedural context
Data Sources
Primary interviews with urology specialists, OEM executives, and procurement managers
Government physician and procedural data
Hospital private datasets
Regulatory and import/export databases
iData Research internal market models and forecasting systems
Markets Covered and Segmentation
Global Urological Endoscope Market Scope
This report includes:
Single-use cystoscopes
Rigid cystoscopes
Reusable flexible cystoscopes (fiber optic and video)
Single-use ureteroscopes
Semi-rigid ureteroscopes
Reusable flexible ureteroscopes (fiber optic and video)
Rigid resectoscopes
Rigid nephroscopes
No further sub-segmentation is included in this report, as noted in the provided insight.
Each device type is analyzed for unit sales, ASPs, market value, and forecast trends in all major global regions.
Competitive Analysis
Olympus
Olympus was the leading competitor in the global urological endoscope market in 2024. The company offers one of the broadest portfolios, covering nearly every category analyzed except nephroscopes. Olympus is especially strong in flexible endoscopy and is recognized worldwide for high-tech imaging solutions, including fiber optic flexible models, video endoscopes, and advanced digital scopes.
Olympus’ market presence is rooted in longstanding surgeon familiarity, strong image quality, comprehensive service networks, and a large installed base. Its leadership in flexible scopes positions it well as hospitals evaluate the balance between reusable and single-use products.
Karl Storz
Karl Storz ranked as the second-leading competitor in 2024. The company is a major supplier in the nephroscope market and holds strong positions across ureteroscope, resectoscope, and cystoscope categories. Karl Storz also offers MTP single-use products across multiple specialties, complementing its reusable portfolio and supporting cross-departmental purchasing.
With a large reusable base and growing single-use additions, Karl Storz remains a critical competitor in regions where reusable devices remain the norm.
Boston Scientific
Boston Scientific was the third-leading competitor in the global urological endoscope market in 2024. The company’s entry into the market began with the launch of the LithoVue single-use flexible ureteroscope in 2016. LithoVue helped popularize single-use ureteroscopy globally and continues to drive Boston Scientific’s influence in this category.
The company leverages single-use positioning, strong relationships in stone management, and global distribution channels to compete effectively in urology.
Technology and Practice Trends
Continued shift toward single-use cystoscopes and ureteroscopes, driven by infection control and reduced sterilization workload
Improvements in single-use imaging quality, bringing performance closer to reusable systems
Expanded use of flexible and digital endoscopes for complex stone management procedures
Growth in outpatient and ambulatory procedural volumes, favoring lighter, portable, or single-use models
Cross-specialty use of resectoscopes in gynecology for cervical resections
Integration of digital visualization systems with endoscope towers
Wider training programs for ureteroscopy and nephroscopy, improving procedural efficiency
Increased emphasis on cost-effectiveness analysis for reusable versus single-use scope selection
Technological refinement and infection control priorities will continue shaping purchasing decisions and long term device demand.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
North America remains one of the fastest adopters of single-use scopes, driven by infection control standards and robust outpatient surgery infrastructure. Europe maintains strong reusable scope penetration but is seeing greater evaluation of single-use alternatives as newer models enter the market. Asia Pacific is the fastest-growing region overall due to rapid healthcare expansion, demographic aging, and rising stone prevalence. Latin America and the Middle East show emerging growth as urology departments modernize and endoscopic procedure volumes increase.
Why This Report
This report helps answer key strategic questions for manufacturers, investors, and health systems, including:
Which urological endoscope categories are growing fastest and why
How single-use adoption will impact reusable scope sales and service revenue
How BPH and stone disease prevalence will influence endoscope demand
How demographic aging and global obesity contribute to procedural growth
How shifts in reimbursement affect capital purchasing cycles
Which competitors are best positioned for long term growth
How hospitals balance cost, infection control, and device performance in purchasing decisions
How to plan pricing, product development, or geographic expansion strategies based on forecast demand
The Global Urological Endoscope Market Report from iData Research provides comprehensive insight into every major factor shaping this rapidly evolving device market.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows.
Executive Summary
The global urological endoscope market was valued at over $1.4 billion in 2024. The market is projected to grow at a 12.9 percent CAGR, reaching $3.4 billion by 2032. This rapid expansion is driven by rising BPH and urinary stone prevalence, the shift toward minimally invasive treatment protocols, heightened infection control awareness, and the accelerating adoption of single-use endoscopes.
This report covers all major categories of urological endoscopes, including single-use, rigid, and reusable flexible cystoscopes; single-use, semi-rigid, and reusable flexible ureteroscopes; rigid resectoscopes; and rigid nephroscopes. Reusable flexible scopes are further divided into fiber optic and video types. Only new endoscope sales are included in this analysis. Refurbished scopes and repair services are excluded.
The study provides units sold, average selling prices, market values, competitive shares, procedure trends, and growth patterns. It includes drivers and limiters, regional demand variation, competitive dynamics, business strategies, and technological innovations. Forecasts extend to 2032, with historical data to 2022.
COVID-19 significantly accelerated single-use adoption. While reusable endoscopes remain dominant, single-use formats have gained strong momentum, especially in infection-sensitive hospitals and high-volume settings where repair costs and sterilization workflows are limiting factors. Meanwhile, rising global procedural volumes for BPH and stone disease continue to fuel overall endoscope demand.
This report provides a comprehensive overview of the global urological endoscope landscape, guiding decision-makers in product strategy, investment planning, competitive positioning, and technology evaluation.
Market Overview
Urological endoscopes are essential diagnostic and interventional tools used to evaluate and treat conditions of the urinary tract, including urinary stones, BPH, strictures, tumors, infections, and congenital abnormalities. They support minimally invasive procedures across urology departments, ambulatory surgery centers, and select outpatient facilities.
The market includes:
Cystoscopes (single-use, rigid, flexible reusable)
Ureteroscopes (single-use, semi-rigid, flexible reusable)
Resectoscopes (rigid)
Nephroscopes (rigid)
Flexible reusable scope categories include fiber optic and video-based models. Each device type serves specific diagnostic and procedural needs:
Cystoscopes are primarily used for bladder examination, tumor assessment, and urethral evaluation.
Ureteroscopes support stone management, strictures, and ureteral tumors.
Nephroscopes are used for percutaneous kidney access and stone removal procedures.
Resectoscopes facilitate BPH and some gynecologic resections.
Adoption varies by region, influenced by reimbursement policies, hospital purchasing capacity, infection control protocols, availability of trained urologists, and the rate of transition to single-use devices.
The market has been reshaped over the last several years by:
COVID-19 infection control practices
Increased attention to cross-contamination risks
Supply of single-use alternatives
Procedural growth tied to stone disease and BPH
Changes in urologist practice structures
Growing outpatient surgical volumes
Endoscope sales correlate closely with procedure volumes. As BPH and stone management grow due to demographic shifts and lifestyle trends, so does the demand for urological endoscopes.
Despite strong growth, hospitals must navigate capital budget limitations, reimbursement changes, and shifts toward refurbished alternatives in price-sensitive environments. These factors balance the short- and medium-term trajectory of each endoscope category.
Market Drivers
Shift to Single-Use Products
The COVID-19 pandemic was a major catalyst for single-use endoscope adoption. In bronchoscopy, single-use devices rapidly became essential tools, and this trend has since spilled into urology, where infection control concerns remain a high priority. Single-use scopes eliminate cross-contamination risk, reduce sterilization burden, and simplify workflow.
The urology market has historically relied on reusable scopes due to clinician familiarity, perceived cost savings, and high image quality. However, as single-use cystoscopes and ureteroscopes have improved, hospitals have expanded their use in outpatient clinics and emergency settings.
Although cost-effectiveness evidence remains mixed, the added infection control assurance and lower repair burden contribute to the growing momentum behind single-use use cases. As more models enter the market, procedure volumes linked to single-use endoscopes will increase.
Procedure Growth
Urological endoscope demand is tied closely to procedural volume. Cystoscopes, ureteroscopes, and nephroscopes are used in stone management, while resectoscopes are used in BPH treatment. These devices are also used in procedures beyond the scope of this report, such as gynecological resections and surveillance for bladder tumors.
As global populations age and healthcare access expands, hospitals treat a greater number of patients requiring:
Stone removal
Ureteral evaluations
Bladder tumor surveillance
BPH management
Urethral repairs
Higher procedure volume translates directly into stronger scope demand. Growth in minimally invasive surgeries also contributes to increased endoscope utilization and replacement cycles.
Demographic Factors
Demographics strongly influence urological procedure volumes. BPH and stone management procedures grow as the population ages. The male population over age 65 is projected to increase significantly during the forecast period. BPH symptoms appear rarely before age 40 but affect:
50 percent of men in their 50s
80 percent of men in their 70s
More than 95 percent of men over 80
Globally, about 22 million men have moderate to severe BPH symptoms. BPH prevalence ranges from 20 to over 60 percent of men over 50, depending on region.
Urinary stones are also tied closely to obesity. Approximately one-third of American adults are obese, and nearly 2 billion adults worldwide are overweight. Excess body weight increases urinary stone formation due to metabolic changes, higher excretion of stone-forming substances, and dietary patterns high in sodium, protein, and sugar.
As obesity rises globally, stone incidence increases, placing additional strain on healthcare systems but also expanding demand for scopes used in endoscopic stone management.
Market Limiters
Reimbursement Cuts
CMS readmission reduction and cost-containment policies in the United States have placed pressure on hospital budgets. Reduced capital income may limit spending on new urological endoscopes. Hospitals may rely more on existing inventory, delay capital purchases, or increase preference for refurbished scopes as cost-saving alternatives.
Similar trends appear in cost-sensitive countries where austerity measures and limited capital availability encourage hospitals to extend device life or pursue pre-owned equipment.
Urologist Practice Setting Changes
The number of small urology practices has been declining due to increasing malpractice costs and administrative overhead. As solo and small group practices close, urologists migrate to hospital employment or large specialty groups. This consolidation could limit device purchasing flexibility, since hospitals maintain centralized purchasing processes and may restrict the number of new devices procured annually.
As purchasing power consolidates, buying cycles can lengthen, affecting the pace at which facilities adopt new technologies.
Decline of Service Revenue
Historically, reusable scope manufacturers benefited from recurring repair and refurbishment revenue. As single-use devices expand and pricing decreases, reusable scope suppliers may be compelled to reduce service pricing to remain competitive. This erodes margins and pressures overall device pricing.
Simultaneously, single-use devices reduce repair needs, removing a historical revenue source for OEMs and service providers. Over time, as single-use scope adoption rises, reusable scope companies may face price compression across both capital and service categories.
Market Coverage and Data Scope
Quantitative Coverage
Market size
Market shares
Market forecasts to 2032
Growth rates
Units sold
Average selling prices
Qualitative Coverage
Market drivers and limiters
Technology shifts and adoption insights
Competitive strategies and SWOT profiles
Mergers and acquisitions
Product portfolios
Regulatory landscape
Disease and procedural context
Data Sources
Primary interviews with urology specialists, OEM executives, and procurement managers
Government physician and procedural data
Hospital private datasets
Regulatory and import/export databases
iData Research internal market models and forecasting systems
Markets Covered and Segmentation
Global Urological Endoscope Market Scope
This report includes:
Single-use cystoscopes
Rigid cystoscopes
Reusable flexible cystoscopes (fiber optic and video)
Single-use ureteroscopes
Semi-rigid ureteroscopes
Reusable flexible ureteroscopes (fiber optic and video)
Rigid resectoscopes
Rigid nephroscopes
No further sub-segmentation is included in this report, as noted in the provided insight.
Each device type is analyzed for unit sales, ASPs, market value, and forecast trends in all major global regions.
Competitive Analysis
Olympus
Olympus was the leading competitor in the global urological endoscope market in 2024. The company offers one of the broadest portfolios, covering nearly every category analyzed except nephroscopes. Olympus is especially strong in flexible endoscopy and is recognized worldwide for high-tech imaging solutions, including fiber optic flexible models, video endoscopes, and advanced digital scopes.
Olympus’ market presence is rooted in longstanding surgeon familiarity, strong image quality, comprehensive service networks, and a large installed base. Its leadership in flexible scopes positions it well as hospitals evaluate the balance between reusable and single-use products.
Karl Storz
Karl Storz ranked as the second-leading competitor in 2024. The company is a major supplier in the nephroscope market and holds strong positions across ureteroscope, resectoscope, and cystoscope categories. Karl Storz also offers MTP single-use products across multiple specialties, complementing its reusable portfolio and supporting cross-departmental purchasing.
With a large reusable base and growing single-use additions, Karl Storz remains a critical competitor in regions where reusable devices remain the norm.
Boston Scientific
Boston Scientific was the third-leading competitor in the global urological endoscope market in 2024. The company’s entry into the market began with the launch of the LithoVue single-use flexible ureteroscope in 2016. LithoVue helped popularize single-use ureteroscopy globally and continues to drive Boston Scientific’s influence in this category.
The company leverages single-use positioning, strong relationships in stone management, and global distribution channels to compete effectively in urology.
Technology and Practice Trends
Continued shift toward single-use cystoscopes and ureteroscopes, driven by infection control and reduced sterilization workload
Improvements in single-use imaging quality, bringing performance closer to reusable systems
Expanded use of flexible and digital endoscopes for complex stone management procedures
Growth in outpatient and ambulatory procedural volumes, favoring lighter, portable, or single-use models
Cross-specialty use of resectoscopes in gynecology for cervical resections
Integration of digital visualization systems with endoscope towers
Wider training programs for ureteroscopy and nephroscopy, improving procedural efficiency
Increased emphasis on cost-effectiveness analysis for reusable versus single-use scope selection
Technological refinement and infection control priorities will continue shaping purchasing decisions and long term device demand.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
North America remains one of the fastest adopters of single-use scopes, driven by infection control standards and robust outpatient surgery infrastructure. Europe maintains strong reusable scope penetration but is seeing greater evaluation of single-use alternatives as newer models enter the market. Asia Pacific is the fastest-growing region overall due to rapid healthcare expansion, demographic aging, and rising stone prevalence. Latin America and the Middle East show emerging growth as urology departments modernize and endoscopic procedure volumes increase.
Why This Report
This report helps answer key strategic questions for manufacturers, investors, and health systems, including:
Which urological endoscope categories are growing fastest and why
How single-use adoption will impact reusable scope sales and service revenue
How BPH and stone disease prevalence will influence endoscope demand
How demographic aging and global obesity contribute to procedural growth
How shifts in reimbursement affect capital purchasing cycles
Which competitors are best positioned for long term growth
How hospitals balance cost, infection control, and device performance in purchasing decisions
How to plan pricing, product development, or geographic expansion strategies based on forecast demand
The Global Urological Endoscope Market Report from iData Research provides comprehensive insight into every major factor shaping this rapidly evolving device market.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows.
Table of Contents
125 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
